events

#BIOCEO19 Kicks Off in NYC

Pharmaceutical innovation is not slowing down. Last year the FDA approved a total of 59 drugs, exceeding the previous record by 20 percent. Nearly half of those approvals came from smaller companies including 28 that came from firms that had never before received an approval.

These data points are not lost on the more than 600 active investors arriving today for the BIO CEO & Investor Conference (#BIOCEO19) in NYC. The most unique medical breakthroughs often come from small companies working on such innovative technologies as cell therapy, immuno-oncology, gene editing and precision medicine—innovations that have the potential to change the medical landscape. Emerging biotech companies are the very focus of #BIOCEO19—one of the largest investor conferences designed to support public and select private biotech companies at the beginning of the drug development life-cycle.

Gathering today and tomorrow are approximately 1200 attendees from around the globe representing institutional investors, industry analysts, biotech executives and policy makers. The connections made here are the engines that drive innovation for the medicines of tomorrow. Attendees will be engaged through BIO’s One-on-One Partnering™ system, which schedules face-to-face meetings that might otherwise require weeks and costly travel bills to arrange. This year partnering is trending up by 20 percent with 50 new investors and at least 150 new companies that are new to the event. By the time the conference ends, approximately 2,800 meetings will have been scheduled.

During the next two days conference participants can enjoy:

  • Six Fireside Chats lead by biotech executives and leaders in the investment community.
  • Panel sessions on the most cutting-edge science and investment trends as well as public policy analysis.
  • At least 130 company presentations outlining research, discoveries and company pipelines.
  • BIO One-on-One Partnering meetings that facilitate venture investment, deals, and industry collaborations.
  • Networking receptions connecting attendees in an informal setting.
READ  Midphase failure of Novartis’ NASH drug crushes Conatus

Ramping up the social media engagement this year, two of the panel sessions will be live on Facebook!

Market Outlook—Leveraging Market Corrections for M&A or IPOs

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?

Attendees can make their own social media engagement easier with the BIO’s social media toolkit containing speaker handles, sample tweets and more.

Join the conversation using #BIOCEO19 and enjoy the conference!

http://feedproxy.google.com/~r/BiotechNow/~3/SocCP_LqGCk/bioceo19-kicks-off-in-nyc

Advertisements

Leave a Reply